Editorial Picks
Hand-picked stories offering depth, insight, and perspective on global cannabis developments.
Editorial Picks · page 8
- Clinical Research
Rescheduling Will Reprice Medical IP, Not Retail Footprints
US cannabis rescheduling is unlikely to trigger a land grab.
- Industry Trends
Organigram Acquires Sanity Group: When Big Tobacco Moves into Cannabis
By Dr Sebastian Marincolo, Director of Strategic Content & Editorial, Weed.de Canadian cannabis company Organigram Global has agreed to acquire Berlin’s Sanity Group for up to 227 million euros, financed in large part by a roughly 65 million Canadian dollar capital injection from its largest shareholder, British American Tobacco (BAT).
- Press releases
Cannabis Europa Launches Reimagined VIP Experience: A New Standard for Senior Decision Makers
Cannabis Europa has today unveiled a new, fully reimagined, dedicated VIP Experience focused on the needs of senior executives, investors and policymakers shaping the future of Europe’s cannabis industry.
- Clinical Research
Ananda Pharma Cleared to Begin Dosing in NHS-Backed CBD Endometriosis Trial
Ananda Pharma has cleared the final regulatory hurdle needed to begin its ENDOCAN Phase 2 clinical trial, receiving approval from the MHRA and NHS Health Research Authority to commence dosing of its proprietary MRX1 CBD oral solution in women with endometriosis-associated pain.
- Industry Trends
The Scramble for Europe
Last month, the German cannabis market saw its most significant consolidation deal to date, as Canadian heavyweight Organigram announced plans to acquire Sanity Group in a deal worth up to €250m.
- Clinical Research
‘You Can’t Treat What You Can’t Measure’ – The Plan to Make the Endocannabinoid System Impossible to Ignore
Across global cannabis markets, the average levels of THC content are continuing a sustained, exponential and well-documented rise.
- CBD Market
Clinical Evidence vs. Food Law: Europe’s CBD Dilemma
The CBD sector has had a turbulent few weeks on both sides of the Channel, with the European Food Safety Authority (EFSA) terminating four novel food applications, just days after announcing incredibly restrictive new safety limits.
- Industry Trends
US Cannabis Rescheduling: A Victory or a Federal Trap?
US cannabis rescheduling, much like President Donald Trump who is rightly credited for finally pushing it forward, has sucked all the oxygen out of the room for the last two years.
- International Regulation
France’s Medical Cannabis Framework: Built for Patients or for Regulators?
The French medical cannabis market is now in the very final stage of decision-making before being implemented nationally, as the HAS presented its draft for the pricing and reimbursement strategy earlier this week.
- Industry Trends
New Report: Poland Medical Cannabis Market Data Shows Full Post-Ban recovery, With a Catch
Polish pharmacies dispensed nearly 5,450 kilograms of dried cannabis flower in 2025, a 12% increase from the prior year, according to new data obtained by Prohibition Partners.
- Medical Cannabis
Cannabis Europa Paris 2026: France’s Medical Cannabis Reimbursement Plans Revealed
Today (February 19, 2026), Cannabis Europa returns to the French capital for the first time since 2019 at a critical juncture for the incoming French medical cannabis industry.
- Industry Trends
CRS Report Suggests 280E Could be Unconstitutional for Cannabis Businesses
According to recent analysis from the Congressional Research Service, cannabis businesses may not need to wait for rescheduling to challenge the now-notorious 280E tax burden, suggesting that it may be unconstitutional.
